Skip Nav Destination
Issues
1 January 2019
-
Cover Image
Cover Image
About the CoverClose Modal
Although T cells infiltrate melanomas, they usually fail to clear the tumor. Plasmacytoid DCs (PDCs) can regulate T-cell function and, in addition, can eliminate melanomas by TLR-mediated mechanisms. Vescovi et al. show that infiltration by PDCs occurs early in primary cutaneous melanoma and their localization is at the invasive margin, where the PDCs can interact with CD8+ T cells. However, in advanced and metastatic disease, PDCs do not infiltrate into tumor tissues and PDCs in circulation are reduced. This is due to a collapse of the PDC compartment during cancer progression, caused by soluble factors in the melanoma secretome that lead to PDC death and impaired differentiation from progenitor cells. These data highlight that rescuing PDCs could help in inducing antitumor responses. Read more in this issue on page 12. Original image is a primary cutaneous melanoma with little infiltration of PDCs from Fig. 1H. Artwork by Lewis Long. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 2326-6066
EISSN 2326-6074
Journal Archive
Cancer Immunology Research (2013-Present)
(ISSN 2326-6066) Published monthly since 2013.Cancer Immunity (2001-2013; volumes 1-13)
(EISSN 1424-9634) Published periodically from 2001-2013.Table of Contents
What We’re Reading
Meeting Report
Cancer Immunology Miniature
Research Articles
Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome
Raffaella Vescovi; Matilde Monti; Daniele Moratto; Lucia Paolini; Francesca Consoli; Luisa Benerini; Laura Melocchi; Stefano Calza; Mariella Chiudinelli; Giulio Rossi; Mattia Bugatti; Michele Maio; Ester Fonsatti; Camillo Farisoglio; Michele Simbolo; Camillo Almici; Rosanna Verardi; Aldo Scarpa; Paolo Bergese; Ausilia Manganoni; Fabio Facchetti; William Vermi
Author Choice
Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma
Sabrina A. Hogan; Anaïs Courtier; Phil F. Cheng; Nicoletta F. Jaberg-Bentele; Simone M. Goldinger; Manuarii Manuel; Solène Perez; Nadia Plantier; Jean-François Mouret; Thi Dan Linh Nguyen-Kim; Marieke I.G. Raaijmakers; Pia Kvistborg; Nicolas Pasqual; John B.A.G. Haanen; Reinhard Dummer; Mitchell P. Levesque
Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types
Allison R. Greenplate; Daniel D. McClanahan; Brian K. Oberholtzer; Deon B. Doxie; Caroline E. Roe; Kirsten E. Diggins; Nalin Leelatian; Megan L. Rasmussen; Mark C. Kelley; Vivian Gama; Peter J. Siska; Jeffrey C. Rathmell; P. Brent Ferrell; Douglas B. Johnson; Jonathan M. Irish
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister; Joana Murad; Lillian Werner; Heather Daley; Helene Trebeden-Negre; Joanina K. Gicobi; Adam Schmucker; Jake Reder; Charles L. Sentman; David E. Gilham; Frédéric F. Lehmann; Ilene Galinsky; Heidi DiPietro; Kristen Cummings; Nikhil C. Munshi; Richard M. Stone; Donna S. Neuberg; Robert Soiffer; Glenn Dranoff; Jerome Ritz; Sarah Nikiforow
PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer
Sandra Heskamp; Peter J. Wierstra; Janneke D.M. Molkenboer-Kuenen; Gerwin W. Sandker; Soley Thordardottir; Jeannette Cany; Daniel Olive; Johan Bussink; Otto C. Boerman; Harry Dolstra; Erik H.J.G. Aarntzen; Willemijn A. Hobo
Correction
Acknowledgment to Reviewers
Advertisement